Palisade Bio, Inc.
PALI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001357459
In the last 90 days, Palisade Bio, Inc. insiders filed 3 open-market purchases and 2 sales; 124 institutions reported holding it in 13F filings for Q2 2026, worth $362.4M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Palisade Bio, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 23 | 22 | −1 |
| Shares | 2.49M | 766.3K | −1.72M (−69.2%) |
| Value | $10.1M | $2.03M | −$8.09M (−80.0%) |
New holders (2)
Institutions that held Palisade Bio, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Sargent Investment Group, LLC | 105,000 | $278.0K | 0.07% |
| Northwestern Mutual Wealth Management Co | 62 | $0 | 0.00% |
Sold out (3)
Institutions that held Palisade Bio, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Altium Capital Management LP | 1,824,894 | $7.43M |
| Renaissance Technologies LLC | 145,300 | $591.0K |
| Tower Research Capital LLC (TRC) | 909 | $4.00K |